This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum
See You Next Year! 26-28 Feb, 2025
Westin Miyako KyotoKyoto, Japan

Tianjin Orilife


Tianjin Orilife Biopharma Co., Ltd.(referred to as Orilife below) is an enterprise that integrates the research, production, and sales of modified nucleosides, nucleotides, phosphoramidites, nucleic acid drug synthesis carriers, nucleic acid drug delivery carriers, and auxiliary materials for nucleic acid drug synthesis.

Orilife was established as a joint venture between Rianlon Corporation (300596) and GenePharma, relying on GenePharama's 20 years of scientific research and design platform in nucleic acid drug synthesis, nucleotides and delivery vectors, combined with Rianlon's advantages in engineering design, large-scale plant construction, production management and quality control in the field of fine chemicals production, we aim to build a leading international supplier and technical service provider of nucleic acid drug raw materials with superior technology, management and quality.

Orilife has appointed Dr Peizhuo Zhang, Chairman of GemaPharma, as the chief scientist and has set up a team of proficient researchers and developers to provide customer-specific development needs. The company has built a fully DCS automated production unit and strictly follows ISO9001, ISO14001 and ISO45001 management standards to control raw material procurement, process control, finished product testing, environmental protection, safety production, and more. The plant has an annual production capacity of 6000kg, equipped with more than 50 reaction kettles of different specifications from 100L to 5000L to meet the customized production needs of customers in different batches.